We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

106 hedge funds and large institutions have $115M invested in Rigel Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 34 increasing their positions, 34 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

886% more call options, than puts

Call options by funds: $887K | Put options by funds: $90K

0% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 34

0.28% less ownership

Funds ownership: 6.37% → 6.09% (-0.28%)

10% less funds holding

Funds holding: 118 → 106 (-12)

20% less capital invested

Capital invested by funds: $143M → $115M (-$28M)

65% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 17

Holders
106
Holders Change
-12
Holders Change %
-10.17%
% of All Funds
1.68%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
34
Reduced
34
Closed
17
Calls
$887K
Puts
$90K
Net Calls
+$797K
Net Calls Change
-$206K

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$3.75M
2
VOYA Investment Management
VOYA Investment Management
Georgia
+$1.39M
3
SCM
Soleus Capital Management
Connecticut
+$752K
4
GCP
GSA Capital Partners
United Kingdom
+$737K
5
BCM
Bridgeway Capital Management
Texas
+$264K

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$2.49M
2
Two Sigma Investments
Two Sigma Investments
New York
-$1.79M
3
Millennium Management
Millennium Management
New York
-$1.66M
4
TA
Tamarack Advisers
California
-$1.61M
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$1.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
HSBC Holdings
76
HSBC Holdings
United Kingdom
$22.7K +$156 +13 +0.6%
BJL
77
Brighton Jones LLC
Washington
$20.5K – – –
Victory Capital Management
78
Victory Capital Management
Texas
$20.3K +$48 +4 +0.2%
Legal & General Group
79
Legal & General Group
United Kingdom
$20.2K -$2.44K -203 -10%
FPCP
80
Fort Point Capital Partners
California
$18.4K – – –
BCM
81
Bayesian Capital Management
New York
$16.3K -$15.4K -1,280 -46%
AIP
82
Ameritas Investment Partners
Nebraska
$16K – – –
GS
83
GTS Securities
New York
$14.3K +$15.9K +1,320 New
Creative Planning
84
Creative Planning
Kansas
$12.7K +$14.1K +1,175 New
PNC Financial Services Group
85
PNC Financial Services Group
Pennsylvania
$11.9K +$1.2K +100 +10%
HighTower Advisors
86
HighTower Advisors
Illinois
$11K +$12.2K +1,015 New
EGM
87
Engineers Gate Manager
New York
$11K -$120 -10 -1%
IWC
88
Integrated Wealth Concepts
Massachusetts
$10.8K -$12K -1,000 -50%
FHA
89
Flagship Harbor Advisors
Massachusetts
$10.8K – – –
TRCT
90
Tower Research Capital (TRC)
New York
$10.7K -$14.2K -1,182 -54%
MLICM
91
Metropolitan Life Insurance Company (MetLife)
New York
$10.2K – – –
Group One Trading
92
Group One Trading
Illinois
$5.38K +$5.99K +498 New
National Bank of Canada
93
National Bank of Canada
Quebec, Canada
$4.12K -$1.2K -100 -20%
Northwestern Mutual Wealth Management
94
Northwestern Mutual Wealth Management
Wisconsin
$2.75K – – –
Citadel Advisors
95
Citadel Advisors
Florida
$2.34K +$180 +15 +7%
IA
96
IFP Advisors
Florida
$2.13K – – –
LWANC
97
Laurel Wealth Advisors (North Carolina)
North Carolina
$1.62K – – –
Osaic Holdings
98
Osaic Holdings
Arizona
$1.52K – – –
AF
99
Allworth Financial
California
$1.51K – – –
BTI
100
Blue Trust Inc
Georgia
$1K – – –
1 2 3
4
5

RIGL Hedge Fund Activity: Q3 2023 in Review

106 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q3 2023, worth a combined $115M — down 20% from $143M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of RIGL and 6 opened new positions — a net loss of 11 holders — while 34 trimmed existing stakes and 34 added.

The largest buyer was Morgan Stanley, adding an estimated $3.75M. The largest seller was Vanguard Group, cutting an estimated $2.49M.

  • 106 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q3 2023, down from 118 in Q2 2023.
  • Funds reported $115M of Rigel Pharmaceuticals stock for Q3 2023, down 20% quarter-over-quarter.
  • 6 funds opened new Rigel Pharmaceuticals positions in Q3 2023 and 17 closed out, a net change of -11 holders.
  • The largest Rigel Pharmaceuticals buyer in Q3 2023 was Morgan Stanley, an estimated $3.75M added.
  • The largest Rigel Pharmaceuticals seller in Q3 2023 was Vanguard Group, an estimated $2.49M sold.

Based on aggregated 13F filings for Q3 2023.